Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Current pharmacotherapy for inflammatory bowel disease.

B C McKaig1, W A Stack

  • 1Division of Gastroenterology, University Hospital, Queen's Medical Centre, Nottingham, NG7 2UH, UK. brian.mckaig@nottingham.ac.uk

Expert Opinion on Pharmacotherapy
|March 16, 2001
PubMed
Summary

Inflammatory bowel disease (IBD) treatments are evolving beyond traditional therapies. Research is advancing molecular understanding to develop targeted therapies for ulcerative colitis (UC) and Crohn

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Development and roll out of the JETS e-portfolio: a web based electronic portfolio for endoscopists.

Frontline gastroenterology·2017
Same author

Downstaging of colorectal cancer by the National Bowel Cancer Screening programme in England: first round data from the first centre.

Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland·2009
Same author

Increased risk of myocardial infarction as first manifestation of ischaemic heart disease and nonselective nonsteroidal anti-inflammatory drugs.

British journal of clinical pharmacology·2006
Same author

Novel approaches to inflammatory bowel disease.

Expert opinion on investigational drugs·2005
Same author

Interactions between Helicobacter pylori and other risk factors for peptic ulcer bleeding.

Alimentary pharmacology & therapeutics·2002
Same author

Differential expression of TGF-beta isoforms by normal and inflammatory bowel disease intestinal myofibroblasts.

American journal of physiology. Cell physiology·2001

Area of Science:

  • Gastroenterology and Immunology
  • Pharmacology and Therapeutics

Background:

  • Inflammatory bowel disease (IBD), encompassing ulcerative colitis (UC) and Crohn's disease (CD), presents chronic, relapsing enteropathy with unknown causes.
  • Current pharmacotherapy for IBD has remained largely static for over two decades, relying on 5-aminosalicylic acid (5-ASA) preparations, corticosteroids, antibiotics, and immunosuppressants.

Purpose of the Study:

  • To review current IBD therapies and recent impactful studies.
  • To examine the risks and benefits of novel agents currently in clinical trials for IBD.

Main Methods:

  • Literature evaluation of existing IBD therapeutic strategies.
  • Analysis of recent clinical trials and molecular understanding of IBD aetiopathogenesis.
  • Assessment of novel, targeted drug therapies for IBD.

Related Experiment Videos

Main Results:

  • Early IBD trials faced methodological challenges and patient selection difficulties due to disease heterogeneity.
  • Improved research methodology has enhanced molecular understanding of IBD.
  • Development of specific mediator-directed or 'designer' drug therapies for IBD is emerging.

Conclusions:

  • Evidence-based approaches are being established for IBD management through well-designed clinical trials.
  • Optimizing current therapies and evaluating novel agents are key future directions.
  • Advances in molecular understanding are driving the development of targeted IBD therapies.